Skip to content
2000
Volume 17, Issue 6
  • ISSN: 1389-2037
  • E-ISSN: 1875-5550

Abstract

Neurologic disorders are prevalent diseases in the population and represent a major cause of death and disability. Despite the advances made during recent decades, the early diagnosis of these diseases remains a challenge. Determining the pathophysiology of such disorders is also challenging and is a requirement for the development of new drugs and treatments. Molecular neuroimaging studies can help fill these gaps in knowledge by providing clinicians with the tools necessary to diagnose and monitor treatment response and by providing data to help researchers understand the mechanisms of disease. Molecular imaging is a fast-growing field of research, and the development of imaging probes is crucial to molecular imaging research. Imaging based on peptide and small protein molecular probes provides many advantages over traditional neuroimaging for the identification of many pathological aspects of nervous diseases, especially gliomas, for which this type of imaging is gradually being moved to clinical settings. Nonetheless, peptide and small protein imaging also has potential applications in other neurologic diseases such as stroke, Parkinson’s disease and Alzheimer’s disease. This review is focused on the main peptide and small protein probes used for molecular imaging in neurologic disease.

Loading

Article metrics loading...

/content/journals/cpps/10.2174/1389203717666160101123500
2016-09-01
2025-02-02
Loading full text...

Full text loading...

/content/journals/cpps/10.2174/1389203717666160101123500
Loading

  • Article Type:
    Research Article
Keyword(s): Glioma; Molecular imaging; Neurologic diseases; Peptide; PET; Probe; Small protein; SPECT
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test